TRACON Pharmaceuticals Stock Price

0.23 (2.26%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
TRACON Pharmaceuticals Inc TCON NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.23 2.26% 10.40 20:00:00
Open Price Low Price High Price Close Price Prev Close
10.22 10.22 10.83 10.57 10.17
Bid Price Ask Price Spread News
10.25 10.60 0.35 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,515 387,710 $ 10.46 $ 4,053,933 705,619 0.95 - 12.20
Last Trade Time Type Quantity Stock Price Currency
19:59:07 formt 200 $ 10.40 USD

TRACON Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 151.10M 14.53M 14.48M $ - $ - -7.47 -3.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

TRACON Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TCON Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.9711.499.5110.63637,488-0.57-5.2%
1 Month8.1512.207.8310.19777,4842.2527.61%
3 Months5.0512.204.418.46836,9905.35105.94%
6 Months1.8812.201.484.811,202,8058.52453.19%
1 Year3.8612.200.954.30779,8476.54169.43%
3 Years3.1012.200.27813.27434,4617.30235.48%
5 Years7.9212.200.27813.33290,2982.4831.31%

TRACON Pharmaceuticals Description

TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company's pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.